ANI Picks Up US Dermatology Brands From Sandoz
Transaction Follows Soon After Deal For Novitium Pharma
Executive Summary
ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.
You may also be interested in...
ANI Ready For Full-Scale Commercial Launch Of FDA-Approved Cortrophin Gel
ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.
ANI Prepares For Cortrophin Launch
US-based ANI Pharmaceuticals is looking to strengthen its leadership team and strategize a commercial approach for the launch of Cortrophin Gel, as it anticipates FDA approval by 29 October 2021. ANI reported a 2.4% increase in its generics business.
ANI Transforms With Novitium And Sandoz Deals
US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches.